Sandu Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh)
Sandu Pharmaceuticals Ltd · Outcome · 15 Nov 2026, 12:22 am
Sandu Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 1,943 (+10.3% YoY | +18.5% QoQ) ■ EBITDA: 96.4 (+11.8% YoY | +79.5% QoQ) ■ EBITDA Margin (%): 5.0 (+7 bps YoY | +168 bps QoQ) ■ PAT: 78.5 (+49.8% YoY | +244.1% QoQ) ■ EPS (INR): 0.81 (+50.0% YoY | +118.9% QoQ)
Original exchange filing (PDF)
More announcements from Sandu Pharmaceuticals Ltd
- statement of deviation and variation of funds for q ended 30th sept 2026 · 15 Nov 2026
- Results for Q and half year ended 30th sept 2026 · 15 Nov 2026
- Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Approval of Unaudited .... · 14 Nov 2026
- Intimation about change in name of Director from Dr Neeti Madan Kapre to Dr Neeti Gupta · 09 Oct 2026
- Intimation to the holders of Physical Securities to furnish PAN and KYC details · 30 Sept 2026
- 1. Redesignation of shri Balram Viswanathan (DIN :10245195)as Chairman and Managing Director of the company. 2.Appointment of Dr Smt Neeti Kapre (DIN:06801264)as Non Executive Independent Director · 12 Sept 2026
- Appointment of M/s Dave & Dave Chartered Accountant as Statutory Auditor of the Company approved by shareholders in 41st Annual General Meeting · 12 Sept 2026
- 41st Annual General Meeting scrutinizers Report · 12 Sept 2026
